arrow
M

Mirosława Püsküllüoğlu

Maria Sklodowska-Curie National Research Institute of Oncology
H指数:13
被引数:651

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anthocyanin-Rich Freeze-Dried Berry Supplementation in Patients Undergoing Colorectal Cancer Treatment: A Prospective Single-Arm Pilot Study of Tolerability and Longitudinal Inflammatory Biomarker Changes

富含花青素的冻干浆果补充剂在结直肠癌治疗患者中的应用:一项关于耐受性和纵向炎症生物标志物变化的单臂前瞻性试点研究

2026-10-290
OA
Immune-Related Adverse Events of Cemiplimab Therapy in Advanced Cervical Cancer—Data from the Polish–Czech Cervical Cancer Immunotherapy Group (PCCIG-01) with a Review of the Literature

cemiplimab疗法在晚期宫颈癌中的免疫相关不良事件—来自波兰-捷克宫颈癌免疫治疗组(PCCIG-01)的数据及文献综述

2026-05-190
OAAI
Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort

接受sacituzumab govitecan治疗的转移性三阴性乳腺癌患者的联合阳性评分状态: 中欧队列中的相关临床特征和测试模式

2026-02-020
PRE
Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe
2026-01-240
OA
Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from CEBCC-102 study

sacituzumab govitecan在预先治疗的三阴性乳腺癌和脑转移患者中的真实结果: 来自CEBCC-102研究的数据

2026-01-140
PRE
Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study

Sacituzumab govitecan在转移性化生性三阴性乳腺癌患者中的疗效与安全性:一项来自CEBCC-102研究的跨国回顾性病例系列研究

2025-12-090
OAAI
Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety

Sacituzumab Govitecan在波兰转移性三阴性乳腺癌患者中的初始剂量降低:对疗效和安全性的影响

2025-10-040
OA
Strategies for premedication and G-CSF application in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights

曲拉妥珠单抗(sacituzumab govitecan)治疗三阴性乳腺癌患者的预用药及粒细胞集落刺激因子(G-CSF)应用策略:多中心见解

2025-09-280
OA
Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis

基线血红蛋白和嗜中性粒细胞与淋巴细胞比值作为接受sacituzumab govitecan治疗的转移性三阴性乳腺癌患者(二线及以上治疗)的预后生物标志物:一项真实世界分析

2025-09-270
OA
Effectiveness and safety of nivolumab and ipilimumab in older adults with renal cell carcinoma: findings from a multicenter observational study in Poland

纳武利尤单抗和伊匹木单抗在老年肾细胞癌患者中的有效性与安全性:来自波兰一项多中心观察性研究的结果

2025-08-230
OA
Incidence and prevalence of organ toxicities in patients suffering from clear cell renal carcinoma treated with sunitinib and its impact on survival: a reference cancer center experience

透明细胞肾癌患者接受舒尼替尼治疗后器官毒性的发生率和患病率及其对生存的影响:一家参考癌症中心的经验

2025-08-200
OA
Validation of the EORTC information (QLQ-INFO25) and satisfaction with care (IN-PATSAT32) modules in the Polish cancer patient population

EORTC信息(QLQ-INFO25)和护理满意度(IN-PATSAT32)模块在波兰癌症患者人群中的验证

2025-02-130
OA